Psoriasis treatments now include biologics targeting TNF-α, IL-17, and IL-23, but patient response varies. Some patients do not respond or lose response, while others achieve near-complete skin clearance, allowing dose reduction. Clinicians are optimizing doses empirically and investigating this for newer biologics. Therapeutic drug monitoring (TDM) measures drug levels and anti-drug antibodies, helping guide treatment based on exposure-response relationships, which have been identified for newer biologics.
